Spero Therapeutics (NASDAQ:SPRO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a hold rating to a buy rating in a report released on Sunday morning.

SPRO has been the subject of a number of other research reports. Zacks Research downgraded Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Spero Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Spero Therapeutics Stock Performance

Shares of NASDAQ:SPRO opened at $2.45 on Friday. Spero Therapeutics has a 52-week low of $0.51 and a 52-week high of $3.22. The firm has a fifty day moving average of $2.38 and a 200 day moving average of $2.28. The firm has a market capitalization of $138.03 million, a PE ratio of -3.10 and a beta of 1.46.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. Spero Therapeutics had a negative return on equity of 125.91% and a negative net margin of 108.11%.The business had revenue of $5.44 million for the quarter, compared to the consensus estimate of $12.00 million. On average, sell-side analysts forecast that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Insider Buying and Selling at Spero Therapeutics

In other news, insider Esther Rajavelu sold 40,270 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $2.37, for a total value of $95,439.90. Following the transaction, the insider owned 869,450 shares in the company, valued at approximately $2,060,596.50. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors have recently added to or reduced their stakes in SPRO. Invesco Ltd. purchased a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $43,000. Dimensional Fund Advisors LP purchased a new position in shares of Spero Therapeutics during the third quarter valued at about $55,000. Quadrature Capital Ltd bought a new position in Spero Therapeutics in the second quarter worth about $90,000. Capital Asset Advisory Services LLC bought a new position in Spero Therapeutics in the second quarter worth about $94,000. Finally, Axxcess Wealth Management LLC purchased a new stake in Spero Therapeutics in the second quarter worth about $94,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.